Overview

Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole

Status:
Unknown status

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

This study is to explore the optimization of anti-onychomycosis patch with various formulation contents (three patch groups: 3%, 6% and 8% of terbinafine (contains 3-mg, 6-mg and 8-mg/patch terbinafine, respectively) combined with fixed 2% ketoconazole (contains 2-mg ketoconazole/patch) and its safety profile.

Phase:

Phase 1

Details

Lead Sponsor:

Taiwan Biotech Co., Ltd.

Treatments:

Ketoconazole
Terbinafine